Drug ID: 3d00000036
Drug Name: Carfilzomib
Generic Names: Kyprolis
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D :
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Cycle 1- The recommended dose is 20 mg/m².
If tolerated in Cycle 1, the dose should be increased to 27 mg/m² beginning in Cycle 2 and continued at 27 mg/m² in subsequent cycles.
Recommended In: This medication is an antineoplastic agent, prescribed for multiple myeloma. It helps to slow the growth and spread of the cancer.
Directions For Use: It comes as a powder for injection (diluted with fluid) to be administered by a healthcare provider into the vein.
Storage: Store it in refrigerator (2°C to 8°C).
Dosage Forms: Intravenous Injection
Side Effects: Fatigue, anemia, nausea, decrease in platelets, difficulty in breathing, diarrhea, and fever.
In Case of Overdose: There is no known specific antidote for Carfilzomib overdosage. In the event of an overdosage, monitor the patient and provide appropriate supportive care.
Avoid If: Caution should be exercised in patients with history of heart arrest, congestive heart failure, high blood pressure, any allergy, who are taking other medications, during pregnancy and breastfeeding.
It may cause fatigue, dizziness, fainting, and/or low blood pressure, do not drive a car or operate machinery while taking this medication.
Patient may experience shortness of breath, if it is so consult with your healthcare provider.
Drug Interaction: No significant drug interaction is observed yet.